The clinical question remains as to whether stress is a trigger—or at least an exacerbating factor—in psoriasis and if so, how this should influence treatment approaches.
The FDA monitors but does not regulate the use of nail products containing potentially harmful ingredients that are considered safe when used as directed.
In an effort to effectively address global health concerns, the WHO has announced the 13th General Programme of Work, a 5-year strategic plan spanning from 2019 to 2023.
Obesity is an independent risk factor for the development of psoriasis and is associated with a worse prognosis.
Skin disorders, particularly those with known inflammatory mechanisms, may be considered potential early markers for the development of insulin resistance leading to metabolic syndrome, type 2 diabetes, and cardiovascular disease.
We can leverage the agility of machine learning to point out unmet clinical needs and improve clinical practice.
Advocates of direct-pay models have pointed to ways in which out-of-pocket costs of noninsurance accepting practices are often lower than what would be charged under insurance because of copays, deductibles, and stratification of coverage that often excludes all or portions of treatment.
Dermatology Advisor asked 3 practitioners from different regions of the United States how and why they chose their particular practice models.
Current reviews suggest that limited outcomes to individual therapies point to the need for new treatments that target underlying cellular and molecular mechanisms.
Although truly personalized medicine is not yet feasible in psoriasis treatment, a stratified approach to selection of therapies may offer some of the benefits of personalized medicine.
